[Federal Register Volume 85, Number 182 (Friday, September 18, 2020)]
[Notices]
[Pages 58385-58386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20588]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation Nos. 731-TA-1534-1536 (Preliminary)]
Methionine From France, Japan, and Spain; Determinations
On the basis of the record \1\ developed in the subject
investigations, the United States International Trade Commission
(``Commission'') determines, pursuant to the Tariff Act of 1930 (``the
Act''), that there is a reasonable indication that an industry in the
United States is materially injured by reason of imports of methionine
from France, Japan, and Spain, provided for in subheadings 2930.40.00
and 2930.90.46 of the Harmonized Tariff Schedule of the United States,
that are alleged to be sold in the United States at less than fair
value (``LTFV'').\2\
---------------------------------------------------------------------------
\1\ The record is defined in Sec. 207.2(f) of the Commission's
Rules of Practice and Procedure (19 CFR 207.2(f)).
\2\ 85 FR 52324 (August 25, 2020).
---------------------------------------------------------------------------
Commencement of Final Phase Investigations
Pursuant to section 207.18 of the Commission's rules, the
Commission also gives notice of the commencement of the final phase of
its investigations. The Commission will issue a final phase notice of
scheduling, which will be published in the Federal Register as provided
in section 207.21 of the Commission's rules, upon notice from the U.S.
Department of Commerce (``Commerce'') of affirmative
[[Page 58386]]
preliminary determinations in the investigations under Sec. 733(b) of
the Act, or, if the preliminary determinations are negative, upon
notice of affirmative final determinations in those investigations
under Sec. 735(a) of the Act. Parties that filed entries of appearance
in the preliminary phase of the investigations need not enter a
separate appearance for the final phase of the investigations.
Industrial users, and, if the merchandise under investigation is sold
at the retail level, representative consumer organizations have the
right to appear as parties in Commission antidumping investigations.
The Secretary will prepare a public service list containing the names
and addresses of all persons, or their representatives, who are parties
to the investigations.
Background
On July 29, 2020, Novus International, Inc., St. Charles, Missouri,
filed petitions with the Commission and Commerce, alleging that an
industry in the United States is materially injured or threatened with
material injury by reason of LTFV imports of methionine from France,
Japan, and Spain. Accordingly, effective July 29, 2020, the Commission
instituted antidumping duty investigation Nos. 731-TA-1534-1536
(Preliminary).
Notice of the institution of the Commission's investigations and of
a public conference through video conferencing to be held in connection
therewith was given by posting copies of the notice in the Office of
the Secretary, U.S. International Trade Commission, Washington, DC, and
by publishing the notice in the Federal Register of August 4, 2020 (85
FR 47243). In light of the restrictions on access to the Commission
building due to the COVID-19 pandemic, the Commission conducted its
conference through written testimony and video conference on August 19,
2020. All persons who requested the opportunity were permitted to
participate.
The Commission made these determinations pursuant to Sec. 733(a)
of the Act (19 U.S.C. 1673b(a)). It completed and filed its
determinations in these investigations on September 14, 2020. The views
of the Commission are contained in USITC Publication 5120 (September
2020), entitled Methionine from France, Japan, and Spain: Investigation
Nos. 731-TA-1534-1536 (Preliminary).
By order of the Commission.
Issued: September 14, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020-20588 Filed 9-17-20; 8:45 am]
BILLING CODE 7020-02-P